The association between antidepressants use and development of cognitive impairment among older women diagnosed with breast cancer.


Journal

European geriatric medicine
ISSN: 1878-7649
Titre abrégé: Eur Geriatr Med
Pays: Switzerland
ID NLM: 101533694

Informations de publication

Date de publication:
12 2020
Historique:
received: 31 01 2020
accepted: 11 06 2020
pubmed: 24 6 2020
medline: 19 8 2021
entrez: 24 6 2020
Statut: ppublish

Résumé

This study aimed to evaluate the association between the development of cognitive impairment and the use of antidepressants among older women with breast cancer. This retrospective cohort study used the United States National Cancer Institute's Surveillance, Epidemiology, and End Results-Medicare database to identify women who were 67 years old and older and had breast cancer between 2008 and 2013. Propensity scoring was used to account for confounding pre-treatment factors, and Cox proportional hazards modeling was used to examine the risk of developing cognitive impairment among patients based on whether they used antidepressants. A total of 3174 women taking antidepressants (mean age 75.2 ± 6.4) were matched with 3174 women not taking antidepressants (mean age 75.4 ± 6.7). Antidepressant use was associated with a significantly increased risk of cognitive impairment (hazard ratio [HR]: 1.33, 95%; confidence interval [CI]: 1.18-1.48). Additionally, we found that older women without a history of depression or anxiety who use antidepressants have a higher risk of developing cognitive impairment than those who did not use antidepressants (HR: 1.53, 95%; CI: 1.34-1.75 and HR: 1.39, 95%; CI: 1.23-1.56, respectively). Subgroup analysis showed that the use of non-tricyclic antidepressants (TCAs) was associated with a higher risk of cognitive impairment. We found that non-TCA antidepressant use in older women with breast cancer was associated with a higher risk of cognitive impairment. This association was also observed among older women without depression or anxiety who used antidepressants.

Identifiants

pubmed: 32572725
doi: 10.1007/s41999-020-00349-4
pii: 10.1007/s41999-020-00349-4
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1017-1026

Références

Coughlin SS, Paxton RJ, Moore N, Stewart JL, Anglin J (2019) Survivorship issues in older breast cancer survivors. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-05078-8
doi: 10.1007/s10549-018-05078-8 pubmed: 31493034
Ahles TA, Root JC (2018) Cognitive effects of cancer and cancer treatments. Annu Rev Clin Psychol. https://doi.org/10.1146/annurev-clinpsy-050817-084903
doi: 10.1146/annurev-clinpsy-050817-084903 pubmed: 29345974
Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. https://doi.org/10.1093/annonc/mdm500
doi: 10.1093/annonc/mdm500 pubmed: 17974553
Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS et al (2008) Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-007-9686-5
doi: 10.1007/s10549-007-9686-5 pubmed: 17674194
Mandelblatt JS, Stern RA, Luta G, McGuckin M, Clapp JD, Hurria A et al (2014) Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol. https://doi.org/10.1200/JCO.2013.54.2050
doi: 10.1200/JCO.2013.54.2050 pubmed: 25071135 pmcid: 4129505
Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. https://doi.org/10.1212/WNL.0b013e31828726f5
doi: 10.1212/WNL.0b013e31828726f5 pubmed: 23390181 pmcid: 3719424
Kelley AS, McGarry K, Gorges R, Skinner JS (2015) The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med. https://doi.org/10.7326/M15-0381
doi: 10.7326/M15-0381 pubmed: 26502320 pmcid: 4809412
Katon W, Lyles CR, Parker MM, Karter AJ, Huang ES, Whitmer RA (2012) Association of depression with increased risk of dementia in patients with type 2 diabetes: the Diabetes and aging study. Arch Gen Psychiatry. https://doi.org/10.1001/archgenpsychiatry.2011.154
doi: 10.1001/archgenpsychiatry.2011.154 pubmed: 22566583 pmcid: 3840955
Borda MG, Santacruz JM, Aarsland D, Camargo-Casas S, Cano-Gutierrez CA, Suarez-Monsalve S et al (2019) Association of depressive symptoms and subjective memory complaints with the incidence of cognitive impairment in older adults with high blood pressure. Eur Geriatr Med. https://doi.org/10.1007/s41999-019-00185-1
doi: 10.1007/s41999-019-00185-1 pubmed: 31186819 pmcid: 6557430
Yuan Y, Min HS, Lapane KL, Rothschild AJ, Ulbricht CM (2020) Depression symptoms and cognitive impairment in older nursing home residents in the USA: a latent class analysis. Int J Geriatr Psychiatry. https://doi.org/10.1002/gps.5301
doi: 10.1002/gps.5301 pubmed: 32250496 pmcid: 7552436
Dotson VM, McClintock SM, Verhaeghen P, Kim JU, Draheim AA, Syzmkowicz SM et al (2020) Depression and cognitive control across the lifespan: a systematic review and meta-analysis. Neuropsychol Rev. https://doi.org/10.1007/s11065-020-09436-6
doi: 10.1007/s11065-020-09436-6 pubmed: 33052553
Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimäki M et al (2017) Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2017.0660
doi: 10.1001/jamapsychiatry.2017.0660 pubmed: 28514478 pmcid: 5710246
Krebber AMH, Buffart LM, Kleijn G, Riepma IC, de Bree R, Leemans CR et al (2014) Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. https://doi.org/10.1002/pon.3409
doi: 10.1002/pon.3409 pubmed: 24105788
Fisch MJ, Zhao F, Manola J, Miller AH, Pirl WF, Wagner LI (2015) Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psychooncology. https://doi.org/10.1002/pon.3606
doi: 10.1002/pon.3606 pubmed: 24930693
Park S-C (2019) Neurogenesis and antidepressant action. Cell Tissue Res. https://doi.org/10.1007/s00441-019-03043-5
doi: 10.1007/s00441-019-03043-5 pubmed: 31165247
Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ (2006) Serotonin and human cognitive performance. Curr Pharm Des. https://doi.org/10.2174/138161206777698909
doi: 10.2174/138161206777698909 pubmed: 16842171
Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A et al (2011) Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci. https://doi.org/10.1073/pnas.1107411108
doi: 10.1073/pnas.1107411108 pubmed: 21873225
Shen F, Smith JA, Chang R, Bourdet DL, Tsuruda PR, Obedencio GP et al (2011) 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2011.02.026
doi: 10.1016/j.neuropharm.2011.02.026 pubmed: 22227558 pmcid: 3189263
Mowla A, Mosavinasab M, Pani A (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. https://doi.org/10.1097/JCP.0b013e31802e0002
doi: 10.1097/JCP.0b013e31802e0002 pubmed: 17873706
Mokhber N, Abdollahian E, Soltanifar A, Samadi R, Saghebi A, Haghighi MB et al (2014) Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry. https://doi.org/10.1055/s-0034-1377041
doi: 10.1055/s-0034-1377041 pubmed: 24955552
Choe YM, Kim KW, Jhoo JH, Ryu SH, Seo EH, Sohn BK et al (2016) Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease. Int J Geriatr Psychiatry. https://doi.org/10.1002/gps.4384
doi: 10.1002/gps.4384 pubmed: 26553313
Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL et al (2012) Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. https://doi.org/10.1097/JGP.0b013e31826ce4c5
doi: 10.1097/JGP.0b013e31826ce4c5 pubmed: 23032478 pmcid: 3508666
Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R et al (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. https://doi.org/10.1016/S0140-6736(11)60830-1
doi: 10.1016/S0140-6736(11)60830-1 pubmed: 22000130
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z et al (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2014.93
doi: 10.1001/jama.2014.93 pubmed: 24549548 pmcid: 4086818
Kessing LV, Forman JL, Andersen PK (2011) Do continued antidepressants protect against dementia in patients with severe depressive disorder? Int Clin Psychopharmacol. https://doi.org/10.1097/YIC.0b013e32834ace0f
doi: 10.1097/YIC.0b013e32834ace0f pubmed: 21876441
Ravaglia G, Forti P, Lucicesare A, Rietti E, Pisacane N, Mariani E et al (2008) Prevalent depressive symptoms as a risk factor for conversion to mild cognitive impairment in an elderly Italian cohort. Am J Geriatr Psychiatry. https://doi.org/10.1097/JGP.0b013e318181f9b1
doi: 10.1097/JGP.0b013e318181f9b1 pubmed: 18827230
Goveas JS, Hogan PE, Kotchen JM, Smoller JW, Denburg NL, Manson JE et al (2012) Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women's Health Initiative Memory Study. Int Psychogeriatr. https://doi.org/10.1017/S1041610211002778
doi: 10.1017/S1041610211002778 pubmed: 22301077 pmcid: 5800401
Saczynski JS, Rosen AB, McCammon RJ, Zivin K, Andrade SE, Langa KM et al (2015) Antidepressant use and cognitive decline: the health and retirement study. Am J Med. https://doi.org/10.1016/j.amjmed.2015.01.007
doi: 10.1016/j.amjmed.2015.01.007 pubmed: 26714211 pmcid: 4879087
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. https://doi.org/10.1097/01.MLR.0000020942.47004.03
doi: 10.1097/01.MLR.0000020942.47004.03 pubmed: 12187174
Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol. https://doi.org/10.1016/s0895-4356(00)00256-0
doi: 10.1016/s0895-4356(00)00256-0 pubmed: 11146273
Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, Teng Y et al (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA. https://doi.org/10.1001/jama.2013.8272
doi: 10.1001/jama.2013.8272 pubmed: 24327042
Heck JE, Albert SM, Franco R, Gorin SS (2008) Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc. https://doi.org/10.1111/j.1532-5415.2008.01848.x
doi: 10.1111/j.1532-5415.2008.01848.x pubmed: 18691280
Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG et al (2000) Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry. https://doi.org/10.1176/appi.ajp.157.12.1949
doi: 10.1176/appi.ajp.157.12.1949 pubmed: 11097959
Mandelli L, Serretti A, Colombo C, Florita M, Santoro A, Rossini D et al (2006) Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci. https://doi.org/10.1111/j.1440-1819.2006.01564.x
doi: 10.1111/j.1440-1819.2006.01564.x pubmed: 16958944
Culang ME, Sneed JR, Keilp JG, Rutherford BR, Pelton GH, Devanand DP et al (2009) Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry. https://doi.org/10.1097/jgp.0b013e3181b4bf4a
doi: 10.1097/jgp.0b013e3181b4bf4a pubmed: 19916207 pmcid: 3852681
Prado CE, Watt S, Crowe SF (2018) A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol Rev. https://doi.org/10.1007/s11065-018-9369-5
doi: 10.1007/s11065-018-9369-5 pubmed: 29446012
Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH et al (2011) Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry. https://doi.org/10.1001/archgenpsychiatry.2010.184
doi: 10.1001/archgenpsychiatry.2010.184 pubmed: 21969457 pmcid: 3383852
Wang C, Gao S, Hendrie HC, Kesterson J, Campbell NL, Shekhar A et al (2016) Antidepressant use in the elderly is associated with an increased risk of dementia. Alzheimer Dis Assoc Disord. https://doi.org/10.1097/WAD.0000000000000103
doi: 10.1097/WAD.0000000000000103 pubmed: 26999577 pmcid: 4919236
Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB et al (2004) Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. https://doi.org/10.1001/jama.291.24.2959
doi: 10.1001/jama.291.24.2959 pubmed: 15213207
Espeland MA, Rapp SR, Manson JE, Goveas JS, Shumaker SA, Hayden KM et al (2017) Long-term effects on cognitive trajectories of postmenopausal hormone therapy in two age groups. J Gerontol A Biol Sci Med Sci. https://doi.org/10.1093/gerona/glw156
doi: 10.1093/gerona/glw156 pubmed: 28364543 pmcid: 5861908
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D et al (2011) Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. https://doi.org/10.1111/j.1532-5415.2011.03491.x
doi: 10.1111/j.1532-5415.2011.03491.x pubmed: 21707557 pmcid: 3196375
Fox C, Livingston G, Maidment ID, Coulton S, Smithard DG, Boustani M et al (2011) The impact of anticholinergic burden in Alzheimer's dementia—the LASER-AD study. Age Ageing. https://doi.org/10.1093/ageing/afr102
doi: 10.1093/ageing/afr102 pubmed: 21926432
Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA et al (2010) Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. https://doi.org/10.1212/WNL.0b013e3181e7f2ab
doi: 10.1212/WNL.0b013e3181e7f2ab pubmed: 20720188 pmcid: 2905930
Campbell NL, Lane KA, Gao S, Boustani MA, Unverzagt F (2018) Anticholinergics influence transition from normal cognition to mild cognitive impairment in older adults in primary care. Pharmacotherapy. https://doi.org/10.1002/phar.2106
doi: 10.1002/phar.2106 pubmed: 29600808 pmcid: 6036636
Mlyniec K, Nowak G (2013) GPR39 up-regulation after selective antidepressants. Neurochem Int. https://doi.org/10.1016/j.neuint.2013.02.024
doi: 10.1016/j.neuint.2013.02.024 pubmed: 23474197
Craddock TJ, Tuszynski JA, Chopra D, Casey N, Goldstein LE, Hameroff SR et al (2012) The zinc dyshomeostasis hypothesis of Alzheimer's disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0033552
doi: 10.1371/journal.pone.0033552 pubmed: 22761654 pmcid: 3382613
Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD, Markesber WR (2000) Serum zinc levels and Alzheimer's disease. Biol Trace Elem Res. https://doi.org/10.1385/bter:75:1-3:79
doi: 10.1385/bter:75:1-3:79 pubmed: 11051598

Auteurs

Yasser Alatawi (Y)

Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, 7970 King Fahad Rd, Tabuk, 47713-2611, Saudi Arabia. yasser@ut.edu.sa.
Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn University, Auburn, AL, USA. yasser@ut.edu.sa.

Richard A Hansen (RA)

Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn University, Auburn, AL, USA.

Chiahung Chou (C)

Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn University, Auburn, AL, USA.
Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.

Jingjing Qian (J)

Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn University, Auburn, AL, USA.

Vishnu Suppiramaniam (V)

Harrison School of Pharmacy, Department of Drug Discovery and Development, Auburn University, Auburn, AL, USA.

Guanqun Cao (G)

Department of Mathematics and Statistics, Auburn University, Auburn, AL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH